A professional investor tells us where he’d put his money. This week, Nicholas Price, portfolio manager of the Fidelity Japan Trust, highlights three favourites.
Japan’s delayed reopening and the return of tourists are supporting growth in consumption and demand for services. The economy is also transitioning to a moderately inflationary state as companies are increasing wages and finding it easier to raise prices. There is growing pressure on firms to enhance their corporate value and use excess cash to increase investments and shareholders’ returns.
We are also seeing the rationalisation of corporate structures and reductions in cross-shareholdings. While signs of weakness in China’s recovery and the risk of a US recession are potential headwinds, this accumulation of positive factors is supportive of the mid-to-long-term outlook for the Japanese market.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
In terms of investment opportunities, Japan’s technology and materials sectors hold promise. Globally competitive companies in semiconductor equipment and electronic components are trading on compelling valuations as we approach the trough of the cycle. There are also niche chemicals firms that command dominant positions in their global markets yet continue to fly under the radar. Another area of the market that I would highlight is the mid-and small-cap growth segment, which is trading at cheap valuations.
Osaka Soda (Tokyo: 4046) is a chemicals company that has transformed its portfolio from highly cyclical, commodity products to more secular growth solutions. Since 2010 the group has expanded its healthcare business and has established a dominant position in chromatographic purification materials, a vital process for the manufacture of GLP-1 and insulin drugs. With GLP-1 drugs, which help manage blood sugar (glucose) levels in patients with Type-2 diabetes, further expanding into obesity treatment, the company is well positioned to meet the rapid growth in demand from global drug makers. Furthermore, the group’s profitability and free cash flow generation have shown a remarkable improvement owing to the high-profit margin of its purification-material business.
Chemicals group NOF (Tokyo: 4403) commands dominant positions in niche markets, underpinning stable growth in earnings and a high level of profitability. Its core businesses include surfactants (inputs for toiletries and cosmetics) and drug-delivery systems (DDS), which are utilised in mRNA medical technology. While the stock has yet to receive the full recognition it deserves given the strength of its fundamentals, our engagement with management has helped to deliver improvements in disclosure relating to the group’s finances and its environmental and social governance (ESG) policies. We think that enhanced communication with the market and the unwinding of cross-shareholdings will support a re-rating.
Flourishing funeral service firm Kosaido (Tokyo: 7868) is a funeral service operator in Tokyo. The company owns and runs six crematoriums and funeral halls in prime locations. The cremation business boasts an effective monopoly position and high profit margins owing to limited land supply and barriers to new entrants. Moreover, Japan’s ageing society and the net influx into Tokyo will drive demand for cremation over the long term. Meanwhile, Kosaido is starting to utilise its property to expand the funeral-ceremony rental business, aiming to cross-sell its cremation and funeral services. Given its central location and cost advantages, Kosaido should continue gaining share in the funeral services market.
This article was first published in MoneyWeek's magazine. Enjoy exclusive early access to news, opinion and analysis from our team of financial experts with a MoneyWeek subscription.
-
Rachel Reeves's Spring Statement: what we know so farChancellor Rachel Reeves will deliver her Spring Statement to Parliament on Wednesday, 26 March. Tax changes are not expected but spending cuts could be on the horizon.
-
8 of the best energy-efficient properties for saleThe best energy-efficient properties for sale – from a HUF HAUS in London’s Dulwich Village to a contemporary property in the Lake District National Park
-
Find tomorrow’s Asian giants while they are still smaller companiesOpinion Nitin Bajaj, portfolio manager of the Fidelity Asian Values trust, picks three Asian companies to invest in.
-
AI will maintain Moody’s market lead, says Stephen ConnollyOpinion Veteran data provider Moody's has adapted well to the modern world, and is one of Warren Buffett’s longest-held investments
-
Is BlackRock World Mining gearing for a recovery?Opinion After a frustrating year, BlackRock World Mining is positioned for growth and to capitalise on the sector's recovery
-
Should you limit exposure to US tech stocks?An end to the AI boom would shake both US funds and global trackers. Here’s one way to trim exposure to US tech stocks
-
The mystery of America’s gold and why an audit mattersHow much gold does the US actually have? Dominic Frisby explains why it matters
-
Art vs AI: artists’ uprising takes on the botsAI performs impressively, but it’s all based on human work that was taken without payment. The government thinks this is fine. Copyright holders beg to differ
-
The benefits of a stock bubbleOpinion We tend to think of stock bubbles as bad things but, as the dotcom craze shows, good things can come from them, says Matthew Lynn
-
Why CEOs deserve a pay riseOpinion The CEOs of big companies often come under fire for being grossly overpaid. But the truth, as per some economists, is the opposite. Do they merit a pay rise?
